Malignant Melanoma (Suspicious Lesion)

1. Executive Overview: Understanding Malignant Melanoma

Malignant melanoma represents the most lethal form of skin cancer, originating from the malignant transformation of melanocytes—the pigment-producing cells located within the basal layer of the epidermis. Unlike basal cell or squamous cell carcinomas, which are generally more localized, melanoma possesses a high propensity for early lymphatic and hematogenous metastasis if not intercepted during its radial growth phase.

A "suspicious lesion" is a clinical designation used by dermatologists to describe a pigmented growth that deviates from normal cutaneous architecture. Early detection is the single most significant prognostic factor; when diagnosed in situ (Stage 0) or at an early invasive stage (Stage I), the five-year survival rate exceeds 95%. However, once the malignancy penetrates deeper into the dermis or spreads to regional lymph nodes, the therapeutic complexity and mortality risk increase substantially. This guide provides a clinical framework for understanding the biological underpinnings, diagnostic rigors, and evidence-based therapeutic pathways associated with malignant melanoma.

2. Pathophysiology, Etiology, and Risk Factors

The Biological Mechanism

Melanoma arises from the dysregulated proliferation of melanocytes. The transition from a benign melanocytic nevus to a malignant melanoma is driven by the accumulation of genetic mutations, most notably in the BRAF, NRAS, and KIT pathways. Exposure to ultraviolet (UV) radiation—specifically UVA and UVB—induces DNA damage, leading to the formation of pyrimidine dimers. If the cell’s nucleotide excision repair (NER) mechanism fails, these mutations become permanent, leading to the uncontrolled cellular division that characterizes malignancy.

Risk Factor Stratification

The etiology is multifactorial, involving a synergistic relationship between genetic predisposition and environmental exposure.

3. Signs, Symptoms, and Clinical Presentation

The clinical diagnosis of a suspicious lesion relies heavily on the ABCDE criteria, a mnemonic used to identify lesions that warrant immediate histopathological evaluation.

• Asymmetry: One half of the lesion does not mirror the other.
• Border: Irregular, notched, blurred, or ragged edges.
• Color: Variations in pigment, including shades of brown, black, blue, red, or white.
• Diameter: Greater than 6 mm (the size of a pencil eraser), though early melanomas can be smaller.
• Evolving: Any change in size, shape, color, or the development of new symptoms such as pruritus (itching), bleeding, or crusting.

Clinical Variants

1. Superficial Spreading Melanoma: The most common form, characterized by a slow radial growth phase.
2. Nodular Melanoma: An aggressive form that grows vertically, often appearing as a firm, rapidly enlarging bump.
3. Lentigo Maligna Melanoma: Typically found on chronically sun-damaged skin (face/neck) in older individuals.
4. Acral Lentiginous Melanoma: Found on the palms, soles, or under the nails; notably common in darker skin phenotypes.

4. Standard Diagnostic Evaluation & Workup

When a dermatologist identifies a suspicious lesion, a systematic approach is mandated to confirm the diagnosis and determine the stage.

Dermatoscopy (Gold Standard Screening)

Dermatoscopy is a non-invasive diagnostic technique that uses polarized light to visualize subsurface structures. Clinicians look for specific patterns such as atypical pigment networks, blue-white veils, and irregular vascular patterns that are invisible to the naked eye.

Biopsy Procedures

A definitive diagnosis can only be established via histopathology.
* Excisional Biopsy: The gold standard. The entire lesion is removed with a narrow margin (1–3 mm).
* Punch Biopsy: Used for larger lesions or those in difficult anatomical locations; however, it may miss diagnostic features if the sample is not representative.
* Shave Biopsy: Generally discouraged for suspected melanoma due to the risk of "transecting" the tumor, which makes accurate Breslow depth measurement impossible.

Staging (AJCC Guidelines)

Once confirmed, the pathologist measures the Breslow Depth (the thickness of the tumor in millimeters). This is the most critical metric for prognosis. Further workup may include:
* Sentinel Lymph Node Biopsy (SLNB): Recommended for lesions with a Breslow depth >0.8mm to check for microscopic spread.
* Imaging: CT, PET/CT, or MRI may be used in higher-stage disease to screen for distant metastasis (lungs, liver, brain, bone).

5. Therapeutic Interventions

Treatment is determined by the stage of the disease at the time of diagnosis.

Surgical Management

• Wide Local Excision (WLE): The primary treatment for primary cutaneous melanoma. The margins of the excision depend on the Breslow depth (ranging from 1 cm to 2 cm).
• Mohs Micrographic Surgery: Occasionally used for lentigo maligna on the face to spare healthy tissue.

Systemic and Adjuvant Therapies

For advanced or metastatic melanoma, systemic therapy has evolved significantly, shifting away from traditional chemotherapy toward targeted and immunotherapeutic approaches.

1. Immunotherapy: Checkpoint inhibitors (e.g., Pembrolizumab, Nivolumab, Ipilimumab) "release the brakes" on the immune system, allowing T-cells to recognize and destroy melanoma cells.
2. Targeted Therapy: For patients with specific genetic mutations (e.g., BRAF V600), BRAF and MEK inhibitors are highly effective in inducing rapid tumor regression.
3. Adjuvant Therapy: Administered after surgery to high-risk patients to reduce the likelihood of recurrence.

Lifestyle and Surveillance

• Sun Protection: Daily application of broad-spectrum SPF 30+ sunscreen, wearing protective clothing, and avoiding peak UV hours.
• Routine Follow-up: Patients require lifelong surveillance, typically every 3–6 months for the first few years, to monitor for local recurrence or secondary primary melanomas.

6. Frequently Asked Questions (FAQ)

1. Is a suspicious lesion always cancer?
No. Many suspicious lesions turn out to be benign dysplastic nevi (atypical moles) or seborrheic keratoses. However, only a biopsy can confirm this.

2. What is the "Breslow Depth" and why does it matter?
It measures the thickness of the melanoma in millimeters. A thinner tumor generally has a much better prognosis and a lower risk of metastasis.

3. Can melanoma be cured if caught early?
Yes. Melanoma in situ (Stage 0) is effectively cured by complete surgical excision, with a 5-year survival rate nearing 100%.

4. Does sunscreen actually prevent melanoma?
Yes, regular use of broad-spectrum sunscreen reduces the risk of UV-induced DNA damage, which is the primary driver of melanoma.

5. What is a Sentinel Lymph Node Biopsy?
It is a procedure to identify and remove the first lymph node(s) that drain the area of the tumor. It helps determine if the cancer has begun to spread.

6. Are tanning beds really that dangerous?
Yes. Tanning beds emit high levels of UV radiation, which significantly increases the risk of developing melanoma, especially if used before age 30.

7. Can melanoma develop in areas not exposed to the sun?
Yes. Melanoma can occur on the soles of the feet, palms of the hands, under fingernails, and even in the eyes or mucosal membranes.

8. What is the difference between targeted therapy and immunotherapy?
Targeted therapy blocks specific proteins that help cancer cells grow (like the BRAF mutation). Immunotherapy helps your own immune system fight the cancer.

9. How often should I perform a skin self-exam?
Monthly. Use a mirror to check your entire body, including your back, scalp, and between your toes, for any new or changing spots.

10. What is the prognosis for Stage IV melanoma?
While Stage IV is serious, modern immunotherapy and targeted therapies have significantly improved survival rates, shifting the outlook from terminal to a chronic, manageable condition for many patients.

Disclaimer: This information is for educational purposes and does not constitute formal medical advice. If you have a suspicious lesion, please consult a board-certified dermatologist immediately for clinical evaluation.